Literature DB >> 28347675

Equal clinical performance of a novel point-of-care cardiac troponin I (cTnI) assay with a commonly used high-sensitivity cTnI assay.

Per Venge1, Lian van Lippen2, Sabine Blaschke3, Michael Christ4, Felicitas Geier5, Evangelos Giannitsis6, Emil Hagström7, Pierre Hausfater8, Mehdi Khellaf9, Johannes Mair10, David Pariente11, Volkher Scharnhorst12, Veronique Semjonow2.   

Abstract

BACKGROUND: Efficient rule-out of acute myocardial infarction (MI) facilitates early disposition of chest pain patients in emergency departments (ED). Point-of-care (POC) cardiac troponin (cTn) may improve patient throughput. We compared the diagnostic accuracy of a novel cTnI test (Minicare cTnI, Philips), with current POC cTnI (I-Stat, Abbott) and high-sensitivity central laboratory cTnI (hs-cTnI; Architect, Abbott) assays.
METHODS: The clinical performance of the assays were compared in samples from 450 patients from a previous clinical evaluation of Minicare cTnI.
RESULTS: Minicare cTnI correlated with Architect hs-cTnI (r2=0.85, p<0.0001) and I-Stat cTnI (r2=0.93, p<0.0001). Areas under the receiver operating characteristics curves were 0.87-0.91 at admission (p=ns) and 0.96-0.97 3h after admission (p=ns). The negative predictive values (NPV) at admission were 95% ((92-97%, 95% CI) for Minicare cTnI and increased to 99% (97-100%) at 2-4h, and similar to Architect hs-cTnI (98%, 96-100%), but higher than I-Stat cTnI (95%, 92-97%; p<0.01). Negative likelihood ratios (LR-) after 2-4h were 0.06 (0.02-0.17, 95% CI) for Minicare cTnI, 0.11 (0.05-0.24) for Architect hs-cTnI (p=0.02) and 0.28 (0.18-0.43) for I-Stat cTnI (p<0.0001). The clinical concordances between Minicare cTnI and Architect hs-cTnI were 92% (admission) and 95% (2-4h), with lower concordances between Minicare cTnI and I-Stat cTnI (83% and 78%, respectively; p=0.007).
CONCLUSIONS: The Minicare cTnI POC assay may become useful for prompt and safe ruling-out of AMI in ED patients with suspected AMI using a guideline supported 0/3h sampling protocol.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute myocardial infarction; Cardiac troponin I; Emergency medicine; Point-of-care

Mesh:

Substances:

Year:  2017        PMID: 28347675     DOI: 10.1016/j.cca.2017.03.023

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  5 in total

1.  Inkjet-printed point-of-care immunoassay on a nanoscale polymer brush enables subpicomolar detection of analytes in blood.

Authors:  Daniel Y Joh; Angus M Hucknall; Qingshan Wei; Kelly A Mason; Margaret L Lund; Cassio M Fontes; Ryan T Hill; Rebecca Blair; Zackary Zimmers; Rohan K Achar; Derek Tseng; Raluca Gordan; Michael Freemark; Aydogan Ozcan; Ashutosh Chilkoti
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-07       Impact factor: 11.205

2.  Ginkgolide B ameliorates myocardial ischemia reperfusion injury in rats via inhibiting endoplasmic reticulum stress.

Authors:  Changlei Guo; Junbiao Zhang; Peiyong Zhang; Aoyang Si; Zhenling Zhang; Liangping Zhao; Fenghua Lv; Guoan Zhao
Journal:  Drug Des Devel Ther       Date:  2019-02-26       Impact factor: 4.162

3.  Hyperbaric oxygen protects against myocardial reperfusion injury via the inhibition of inflammation and the modulation of autophagy.

Authors:  Chunxia Chen; Wan Chen; Yaoxuan Li; Yanling Dong; Xiaoming Teng; Zhihuan Nong; Xiaorong Pan; Liwen Lv; Ying Gao; Guangwei Wu
Journal:  Oncotarget       Date:  2017-12-04

4.  How to choose a point-of-care testing for troponin.

Authors:  Ya-Hui Lin; Yang Zhang; Yu-Tao Liu; Kai Cui; Jin-Suo Kang; Zhou Zhou
Journal:  J Clin Lab Anal       Date:  2020-03-28       Impact factor: 2.352

5.  Critical appraisal of the 2020 ESC guideline recommendations on diagnosis and risk assessment in patients with suspected non-ST-segment elevation acute coronary syndrome.

Authors:  Evangelos Giannitsis; Stefan Blankenberg; Robert H Christenson; Norbert Frey; Stephan von Haehling; Christian W Hamm; Kenji Inoue; Hugo A Katus; Chien-Chang Lee; James McCord; Martin Möckel; Jack Tan Wei Chieh; Marco Tubaro; Kai C Wollert; Kurt Huber
Journal:  Clin Res Cardiol       Date:  2021-02-26       Impact factor: 5.460

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.